ArticleInternal medicine (Tokyo, Japan)2019
Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentrations in a Hemodialysis Patient.
Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Ceftriaxone encephalopathy in a very elderly dialysis patient.CEN case reports · 2025Article
- An 8-Year 5-Month-Old Boy with a Basal Ganglia Lesion with Triphasic Waves on Electroencephalogram.Actas espanolas de psiquiatria · 2024Article
- Article
- Ceftriaxone-induced encephalopathy in a patient with a normal renal function.BMJ case reports · 2024Article
- Review
- Article
- Ceftriaxone-Induced Encephalopathy in a Patient With End-Stage Renal Disease on Hemodialysis.Cureus · 2023Article
- Two cases of ceftriaxone-induced encephalopathy treated by hemoperfusion in hemodialysis patients.Hemodialysis international. International Symposium on Home Hemodialysis · 2022Article
- Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan.International journal of environmental research and public health · 2022Review
- Encephalopathy induced by high levels of ceftriaxone in the blood and cerebrospinal fluid.IDCases · 2022Article
- Case Report: Triphasic Waves in a 9-Year-Old Girl With Anti-NMDAR Encephalitis.Frontiers in neurology · 2022Article
- Ceftriaxone-induced encephalopathy in a patient with multicentric glioma.Surgical neurology international · 2022Article
- Serious Neurological Adverse Events of Ceftriaxone.Antibiotics (Basel, Switzerland) · 2021Article
- Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?Internal medicine (Tokyo, Japan) · 2019Article
- Author's Reply: Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?Internal medicine (Tokyo, Japan) · 2019Article
- Cefoperazone-Sulbactam Associated Refractory Seizures.Annals of Indian Academy of NeurologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encephalopathy is a rare side effect of cephalosporin treatment. We herein present a case of encephalopathy induced by ceftriaxone, a third-generation cephalosporin, in a patient with renal failure. An 86-year-old woman on maintenance hemodialysis received ceftriaxone for Helicobacter cinaedi bacteremia. Her mental status deteriorated during antibiotic treatment, and an electroencephalogram revealed triphasic waves predominantly in the frontal area. Her consciousness improved after the discontinuation of the antibiotic due to the suspicion of ceftriaxone-induced encephalopathy. This is the first reported case of encephalopathy associated with high plasma and cerebrospinal fluid ceftriaxone concentrations, and provides significant evidence for a causal relationship between the administration of ceftriaxone and the onset of encephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.